{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:22Z","timestamp":1792511482029,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K16243"],"award-info":[{"award-number":["JP22K16243"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clnesp.2024.11.029","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:14:34Z","timestamp":1732666474000},"page":"182-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Selective peroxisome proliferator-activated receptor-\u03b1 modulator improves hypertriglyceridemia and muscle quality in patients with chronic kidney disease: A retrospective observational study"],"prefix":"10.1016","volume":"65","author":[{"given":"Yukari","family":"Mae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-6015","authenticated-orcid":false,"given":"Tomoaki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinako","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2024.11.029_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A\u00a0single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnesp.2024.11.029_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnesp.2024.11.029_bib3","first-page":"465","article-title":"Feasibility of computed tomography-based assessment of skeletal muscle mass in hemodialysis patients","volume":"34","author":"Takata","year":"2021","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10157-021-02142-4","article-title":"Creatinine generation rate can detect sarcopenia in patients with hemodialysis","volume":"26","author":"Mae","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae028","article-title":"Making the invisible visible: imaging techniques for assessing muscle mass and muscle quality in chronic kidney disease","volume":"17","author":"Sabatino","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clnesp.2024.11.029_bib6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.clnu.2023.06.032","article-title":"Sarcopenic obesity and its relation with muscle quality and mortality in patients on chronic hemodialysis","volume":"42","author":"Sabatino","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2024.11.029_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jchf.2022.04.012","article-title":"Association between thigh muscle fat infiltration and incident heart failure: the health ABC study","volume":"10","author":"Huynh","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clnesp.2024.11.029_bib8","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men","volume":"14","author":"Schaeffner","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","article-title":"Analysis of metabolic parameters as predictors of risk in the RENAAL study","volume":"26","author":"Appel","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnesp.2024.11.029_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.clnesp.2024.11.029_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1262-3636(07)70088-5","article-title":"Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes","volume":"30","author":"Hadjadj","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clnesp.2024.11.029_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/ijms21010190","article-title":"Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules","volume":"21","author":"Hosokawa","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2024.11.029_bib13","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.3390\/ijms22094374","article-title":"Pleiotropic effects of sodium-glucose Cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control","volume":"22","author":"Takata","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2024.11.029_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265461","article-title":"Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model","volume":"17","author":"Hamada","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clnesp.2024.11.029_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA Reductase Inhibitor, atorvastatin, in patients with hypertriglyceridemia","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.clnesp.2024.11.029_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnesp.2024.11.029_bib17","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.2337\/dc16-1246","article-title":"Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD annals initiative","volume":"39","author":"Russo","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnesp.2024.11.029_bib18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in Accord type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnesp.2024.11.029_bib20","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnesp.2024.11.029_bib21","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clnesp.2024.11.029_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnesp.2024.11.029_bib23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib24","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022","author":"Okamura","year":"2023","journal-title":"J\u00a0Atherosclerosis Thromb"},{"key":"10.1016\/j.clnesp.2024.11.029_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","article-title":"Pravastatin and cardiovascular risk in moderate chronic kidney disease","volume":"206","author":"Nakamura","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnesp.2024.11.029_bib26","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clnesp.2024.11.029_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113499","article-title":"Atherogenic lipoproteins for the statin residual cardiovascular disease risk","volume":"23","author":"Yanai","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2024.11.029_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clnesp.2024.11.029_bib29","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/ijms20030706","article-title":"Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment","volume":"20","author":"Yokote","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2024.11.029_bib31","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2169\/internalmedicine.6871-20","article-title":"Real-world profile of a selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1) in Japanese patients with renal impairment and dyslipidemia","volume":"60","author":"Komatsu","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.clnesp.2024.11.029_bib32","article-title":"Efficacy and safety of pemafibrate in patients with chronic kidney disease: a retrospective study","volume":"102","author":"Iwasaki","year":"2023","journal-title":"M\u00e9d"},{"key":"10.1016\/j.clnesp.2024.11.029_bib33","doi-asserted-by":"crossref","unstructured":"Ikeda S, Sugihara T, Kihara T, Matsuki Y, Nagahara T, Takata T et\u00a0al. Pemafibrate ameliorates liver dysfunction and fatty liver in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: A retrospective study with the outcome after a mid-term follow-up. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics11122316.","DOI":"10.3390\/diagnostics11122316"},{"key":"10.1016\/j.clnesp.2024.11.029_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.clnesp.2024.11.029_bib35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ncp.10967","article-title":"Bioelectrical impedance analysis-derived phase angle predicts sarcopenia in patients on maintenance hemodialysis","volume":"38","author":"Wang","year":"2023","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.clnesp.2024.11.029_bib36","first-page":"1535","article-title":"Skeletal muscle density measured by computed tomography as a predictor of mortality in patients receiving hemodialysis","volume":"35","author":"Yajima","year":"2022","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcsm.12860","article-title":"Phase angle from bioelectrical impedance analysis is a useful indicator of muscle quality","volume":"13","author":"Akamatsu","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnesp.2024.11.029_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115407","article-title":"Chronic kidney disease-induced muscle atrophy: molecular mechanisms and promising therapies","volume":"208","author":"Wang","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clnesp.2024.11.029_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnesp.2024.11.029_bib40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00011-024-01861-0","article-title":"Association of systemic immune-inflammation index and systemic inflammation response index with chronic kidney disease: observational study of 40,937 adults","volume":"73","author":"Huang","year":"2024","journal-title":"Inflamm Res"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457724015377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457724015377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:47:01Z","timestamp":1737388021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457724015377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"alternative-id":["S2405457724015377"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.11.029","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective peroxisome proliferator-activated receptor-\u03b1 modulator improves hypertriglyceridemia and muscle quality in patients with chronic kidney disease: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}]}}